Metabolic
Eloralintide
Also called LY3841136
per administration
It has been used in people, but no trial has settled how much or how often.
Quick start
Eloralintide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 1–3 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~25.0 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Eloralintide describe 1–3 mg per administration. Descriptive only, not a recommendation.
Consistent with once-weekly administration; phase 1 pharmacokinetics are not established in publication.
An amylin receptor agonist studied for weight reduction in phase 1 research only. No dose-ranging publication fixes a subcutaneous schedule, so no schedule table is shown.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Eloralintide (LY3841136) phase 1 program (Eli Lilly)Early-phase subcutaneous amylin-agonist dosing; no dose-ranging trial has been published.